Bordetella pertusis Vaccines
Creative Biolabs is a world leader in the field of bacterial vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against pertussis caused by Bordetella pertusis and guarantee the finest results for our customers all over the world.
Pertussis (also known as whooping cough or 100-day cough) is an acute respiratory infection marked by severe, spasmodic coughing episodes during the paroxysmal phase which is caused by Bordetella pertussis (B. pertussis). The bacterium is small, rod-shaped, coccoid, or ovoid Gram-negative that is encapsulated and does not produce spores. It can produce a number of virulence factors, including pertussis toxin, adenylate cyclase toxin, filamentous hemagglutinin, and hemolysin. The reservoir of B. pertussis is humans only. It is spread by airborne droplets and the incubation period is 9-10 days on average. Pertussis remains a significant cause of morbidity and mortality in infants younger than 2 years which starts with the symptoms including runny nose, fever, and mild cough.
Combination Vaccine
There are two combination vaccines available that can help prevent pertussis. One is whole-cell vaccine that comprised of diphtheria, tetanus, and pertussis, suitable for babies and children younger than 7 years old. This vaccine is based on standardized strains of B. pertussis that are killed and often treated with formalin. Another similar combination vaccine offers booster protection against tetanus, diphtheria, and pertussis for older children and adults in certain situations. It was made by acellular pertussis and combined with diphtheria and tetanus toxoids, providing an immune response similar to that triggered by direct contact with the pathogen itself. This vaccine uses only pieces of the pertussis bacteria, which results in fewer side effects than the whole-cell preparation.
Subunit Pertussis Vaccines
A novel vaccine for pertussis is the use of outer-membrane vesicles (OMVs) that naturally contain bacterial surface antigens. The vaccine was designed based on OMVs derived from B. pertussis, which range in size from approximately 50 to 200 nm in diameter and enclose many native bacterial antigens within the spherical particles. It can be used as a combined vaccine with at least tetanus and diphtheria toxoids. This vaccine contains a great number of immunogens and conformations close to those found in the causal agents. Moreover, OMVs are 10 times smaller in diameter than whole bacteria, thus possibly increasing the exposure to different cell types. OMVs may furthermore reach immune cells deeper in the tissues that are less accessible for the whole bacteria or large alum particles to induce an immune response. The vaccine formulation has low toxic and likewise attractive from an economic standpoint. Furthermore, our OMV platforms provide development services for new promising vaccines against other Bordetella species.
Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of bacterial vaccine development. We have experts who are able to help you with the vaccine development against pertussis caused by Bordetella pertusis. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
